Physician profile
Jonathan A Verma
NPI 1376836114
$6,153.76
in general payments reported to CMS, 2019-2025
58 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.07 · 2021: $229 · 2022: $333 · 2023: $467 · 2024: $2,240 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,507.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $844.33 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Isoray, INC | $448.50 | 2019-2023 | Brachytherapy Source |
| Janssen Biotech, INC. | $360.47 | 2024-2025 | Carvykti, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $315.65 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Boston Scientific Corporation | $281.71 | 2022-2025 | Spaceoar Vue System - 10ml |
| Siemens Medical Solutions USA, INC. | $276.53 | 2023-2025 | Bravos Afterloader System |
| Genzyme Corporation | $267.93 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $231.86 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.01 | 2024-2025 | |
| Incyte Corporation | $188.41 | 2024-2025 | Jakafi, Monjuvi |
| Eisai INC. | $160.98 | 2023-2025 | |
| Daiichi Sankyo INC. | $147.33 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Jazz Pharmaceuticals INC. | $141.59 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.31 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Tempus Ai, INC | $137.06 | 2024-2025 | Xt Cdx |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gt Medical Technologies, INC | $134.93 | 2022 | |
| Gilead Sciences, INC. | $133.29 | 2024-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $113.83 | 2024-2025 | Libtayo, Lynozyfic |
| Medtronic, INC. | $103.86 | 2021 | |
| Servier Pharmaceuticals LLC | $96.86 | 2024-2025 | |
| Pfizer INC. | $95.11 | 2023-2025 | |
| Bioprotect Medical, INC. | $88.75 | 2024 | Bioprotect Balloon Implant System |
| Lilly USA, LLC | $83.36 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $79.08 | 2024-2025 | |
| Genentech USA, INC. | $67.69 | 2024-2025 | Tecentriq, Itovebi, Phesgo |
| Astellas Pharma US INC | $67.17 | 2024-2025 | Xtandi, Padcev |
| Springworks Therapeutics, INC. | $66.06 | 2024-2025 | Ogsiveo |
| Sirtex Medical INC | $60.92 | 2023-2024 | Sir-Spheres Microspheres |
| Kite Pharma, INC. | $58.55 | 2021-2025 | Yescarta |
| Agios Pharmaceuticals, INC. | $58.22 | 2024-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $55.25 | 2023-2024 | Ultomiris |
| Geron Corporation | $45.89 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $41.71 | 2024-2025 | Xpovio |
| Sobi, INC | $40.38 | 2024 | |
| Genmab U.S., INC. | $40.30 | 2024 | Tivdak, Epkinly |
| Novocure INC. | $33.45 | 2025 | Optune Lua (Novottf-200t) |
| Acrotech Biopharma INC. | $33.17 | 2024 | Beleodaq |
| Dendreon Pharmaceuticals LLC | $32.96 | 2024 | Provenge |
| Azurity Pharmaceuticals, INC. | $25.45 | 2025 | Danziten |
| Aveo Pharmaceuticals, INC. | $23.54 | 2025 | |
| Rigel Pharmaceuticals, INC. | $22.10 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Syndax Pharmaceuticals, INC. | $22.00 | 2025 | |
| Glaxosmithkline, LLC. | $21.87 | 2024 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $21.16 | 2024 | Onivyde |
| Blueprint Medicines Corporation | $20.96 | 2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $20.81 | 2023 | Epkinly, Imbruvica |
| Myovant Sciences INC. | $20.33 | 2022 | |
| Menarini Silicon Biosystems, INC. | $19.68 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.46 | 2025 | Monoferric |
| Octapharma USA, INC. | $19.12 | 2024 | Octagam Immune Globulin (Human) |
| Morphosys, US INC. | $17.89 | 2024 | Monjuvi |
| Caris Mpi, INC. | $17.07 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $16.96 | 2024 | |
| Stemline Therapeutics INC. | $16.14 | 2025 | Orserdu |
| Iovance Biotherapeutics, INC. | $16.12 | 2025 | Amtagvi |
| Blue Earth Diagnostics | $15.12 | 2025 | Posluma |
| Taiho Oncology, INC. | $14.62 | 2024 | |
| Puma Biotechnology, INC. | $13.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.